Home / Tag Archives: sulfonylureas

Tag Archives: sulfonylureas

Could Your “Type 2” Patient Actually Have a Different Disease? New Trial Challenges Diabetes Treatment

Endocrinologist discussing precision treatment options with a patient diagnosed with HNF1A-MODY while reviewing genetic testing and diabetes management results.

When a person develops diabetes at a young age, is not overweight, and has several family members with the condition, is it really type 2 diabetes? In many cases, the answer may be no. A growing body of evidence suggests that thousands of people worldwide are living with HNF1A-MODY, a …

Read More »

Can Your Patient’s DNA Predict Which Diabetes Drug Will Work Best?

DNA double helix beside diabetes medications and a blood glucose meter illustrating precision medicine and pharmacogenomics in diabetes treatment.

Imagine prescribing the same diabetes medication to two patients with nearly identical A1C levels, only to see one achieve excellent glycemic control while the other experiences little benefit or troublesome side effects. This scenario is common in diabetes care and highlights an important question: could genetics explain these differences? Growing …

Read More »

Managing Rapid Improvement on GLP-1 Therapy: When to Adjust the Rest of the Regimen

Diabetes management tools including glucometer showing improved glucose levels, insulin pen, and medication plan for GLP-1 therapy adjustment

Rapid glycemic improvement with GLP-1 therapy is one of the most powerful benefits of modern diabetes care, but it can also create new clinical challenges. When glucose levels drop quickly, patients may face an increased risk of hypoglycemia if other medications are not adjusted in time. So, how do clinicians …

Read More »

Reassessing Hypoglycemia Risk in the Era of Modern Therapies

Physician reviewing continuous glucose monitor data with older adult patient showing low blood sugar alert during diabetes consultation

Managing the risk of hypoglycemia remains a central challenge in diabetes care, even as newer therapies lower the rate of severe events. Although GLP-1 receptor agonists and SGLT2 inhibitors have reshaped treatment strategies, insulin and sulfonylureas are still widely used, especially among older adults and patients with chronic kidney disease …

Read More »